Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
Flora Peyvandi, Professor of Internal Medicine-Hemostasis and Thrombosis Unit, University of Milan, former President of ISTH, shared on X:
“The VWF : GPIbM and VWF:RCo appear the most suitable assays for monitoring VWF activity in iTTP patients treatment with caplacizumab. The VWF:GPIbR have a limited ability to detect caplacizumab’s inhibition. The VWF:Ab assay is unsuitable for this purpose ”
Title: Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction.
Authors: Paola Colpani, Luciano Baronciani, Ilaria Mancini, Cristina Novembrino, Anna Lecchi, Giovanna Cozzi, Pasqualina De Leo, Massimo Boscolo Anzoletti, Silvia La Marca, Marco Boscarino, Maria Teresa Pagliari, Andrea Artoni, Flora Peyvandi
Read the full article here.
Stay updated with Hemostasis Today.
-
Mar 14, 2026, 16:28Abdul Mannan: Advancing VWF Activity Testing Beyond VWF:RCo in Clinical Laboratories
-
Mar 14, 2026, 16:26Rida Fatima: When The Body’s Most Vital Production Unit Stops Working
-
Mar 14, 2026, 16:16Martin Haluzík: Metabolic Risk Factors and Therapeutic Opportunities in Cardiovascular Disease
-
Mar 14, 2026, 16:10Raffaella Colombatti: Proud to Have Authored the New Lancet Seminar on Sickle Cell Disease
-
Mar 14, 2026, 16:05Simon Senanu: D-Dimer – A Small Fragment with Big Clinical Significance
-
Mar 14, 2026, 15:53Ney Carter: Key Advances in the 2026 ACC/AHA Guideline on the Management of Dyslipidemia
-
Mar 14, 2026, 15:45Nicole Odofin: The First Blood Drive Event at Channel 4
-
Mar 14, 2026, 15:41Michael Makris: Romiplostim Use Allows More Chemotherapy to Be Delivered on Time
-
Mar 14, 2026, 15:40Jecko Thachil: Anticoagulation in Patients With Metabolic-Associated Fatty Liver Disease